Oxurion, formerly ThromboGenics, announced that it has enrolled the first patient in a phase 2 open-label multicenter study evaluating the efficacy and safety of intravitreal THR-317, an anti-PIGF (human placental growth factor) antibody, for the treatment of Macular Telangiectasia Type 1 (MacTel 1).
MacTel 1 is a rare disease that affects the macula and can lead to vision loss. There is currently no cure or effective treatment for MacTel 1.
This phase 2 study (THR-317-003 – NCT03669393) plans to enroll 10 patients with macular edema caused by MacTel 1, who will each receive 3 intravitreal THR-317 injections over a period of 2 months. Efficacy and safety of the therapy will be assessed via functional and anatomic endpoints.
This clinical trial is being conducted in line with the Oxurion strategy and mission to expand its focus on developing treatments for other back of the eye diseases, in addition to its novel diabetic eye disease pipeline.
“The start of this phase 2 study is an important step as we look to expand into additional back of the eye disorders, in line with our mission to enhance vision and fight blindness, alongside our diabetic eye disease pipeline, for which multiple important milestones have been achieved over recent months,” Patrik De Haes, MD, Oxurion CEO, said in a company news release. “Research suggests that PIGF could have an important role to play in MacTel 1, leading us to assess the potential of our anti-PIGF candidate THR-317 in a new eye disease area.”